At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.

Alphamers

Our science

Centauri Therapeutics is an immunotherapy company focused on infectious diseases. Centauri’s approach to treating infectious diseases rests upon proprietary Alphamer® technology. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.

7.0m

immunocompromised people in the United States 1

60%

of haematological cancer deaths are infection related 2

$4.6bn

health care costs in the US to treat six antibiotic resistance threats 3

67,000

deaths annually in Europe and US due to drug-resistant bacterial infections 4 5

Bacteria

Latest News and Articles

Centauri welcomes Matthew Bushdyhan

October 25, 2023

We are so pleased to welcome Associate Scientist, Matt Bushdyhan…

Read More

Centauri Welcomes Adam Johnson

October 16, 2023

We are very pleased to welcome Adam Johnson to our…

Read More

Centauri welcomes Dr Dave Chapman

September 25, 2023

Centauri is delighted to welcome Dr Dave Chapman to the…

Read More